{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:56:07Z","timestamp":1793836567439,"version":"4.6.1"},"reference-count":262,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["989658"],"award-info":[{"award-number":["989658"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016286","name":"Urmia University of Medical Sciences","doi-asserted-by":"publisher","award":["2692"],"award-info":[{"award-number":["2692"]}],"id":[{"id":"10.13039\/501100016286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["65014"],"award-info":[{"award-number":["65014"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["65018"],"award-info":[{"award-number":["65018"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lfs.2021.119132","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T18:04:01Z","timestamp":1611684241000},"page":"119132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["The role of regulatory T cells in the pathogenesis and treatment of prostate cancer"],"prefix":"10.1016","volume":"284","author":[{"given":"Vahid","family":"Karpisheh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Mahboubeh","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinaz","family":"Naghavi Sheykholeslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Mohammadpour Saray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Aghebati-Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naime","family":"Majidi Zolbanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Jadidi-Niaragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119132_bb0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2021.119132_bb0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Center","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.lfs.2021.119132_bb0015","first-page":"1103","author":"Al Olama","year":"2014","journal-title":"Haiman CA"},{"key":"10.1016\/j.lfs.2021.119132_bb0020","first-page":"S11","article-title":"Prostatic intraepithelial neoplasia: an overview","volume":"7","author":"Brawer","year":"2005","journal-title":"Reviews in urology"},{"key":"10.1016\/j.lfs.2021.119132_bb0025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7150\/jca.17648","article-title":"Role of tumor microenvironment in tumorigenesis","volume":"8","author":"Wang","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0030","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ijbiomac.2020.11.056","article-title":"Inhibition of HIF-1\u03b1\/EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells","volume":"167","author":"Karpisheh","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.lfs.2021.119132_bb0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2016.12.012","article-title":"CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice","volume":"246","author":"Jadidi-Niaragh","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119132_bb0040","doi-asserted-by":"crossref","first-page":"106338","DOI":"10.1016\/j.prostaglandins.2019.106338","article-title":"Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer","volume":"144","author":"Karpisheh","year":"2019","journal-title":"Prostaglandins & other lipid mediators"},{"key":"10.1016\/j.lfs.2021.119132_bb0045","article-title":"EP4 receptor as a novel promising therapeutic target in colon cancer","volume":"153247","author":"Karpisheh","year":"2020","journal-title":"Pathology-Research and Practice"},{"key":"10.1016\/j.lfs.2021.119132_bb0050","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1007\/s13277-015-4004-z","article-title":"Myeloid-derived suppressor cells in B cell malignancies","volume":"36","author":"Yazdani","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.lfs.2021.119132_bb0055","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb0060","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/jcp.25873","article-title":"Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer","volume":"233","author":"Kazemi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.lfs.2021.119132_bb0065","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/ijms18071542","article-title":"Overcoming oncogenic mediated tumor immunity in prostate cancer","volume":"18","author":"Bryant","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb0070","first-page":"723","article-title":"Cell interactions in the induction of tolerance: the role of thymic lymphocytes","volume":"18","author":"Gershon","year":"1970","journal-title":"Immunology"},{"key":"10.1016\/j.lfs.2021.119132_bb0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1572","article-title":"The Foxp3+ regulatory T cell: a jack of all trades, master of regulation","volume":"9","author":"Tang","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ni.1818","article-title":"Regulatory T cells exert checks and balances on self tolerance and autoimmunity","volume":"11","author":"Wing","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0090","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s13277-013-0743-x","article-title":"The role of natural killer T cells in B cell malignancies","volume":"34","author":"Ghalamfarsa","year":"2013","journal-title":"Tumor Biol."},{"key":"10.1016\/j.lfs.2021.119132_bb0095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s13277-012-0628-4","article-title":"Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumor Biol."},{"key":"10.1016\/j.lfs.2021.119132_bb0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/08923973.2010.513391","article-title":"Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis","volume":"33","author":"Jadidi-Niaragh","year":"2011","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.lfs.2021.119132_bb0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00262-006-0194-y","article-title":"CD4 regulatory T cells in human cancer pathogenesis","volume":"56","author":"Knutson","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2021.119132_bb0110","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","article-title":"Regulatory T cells: how do they suppress immune responses?","volume":"21","author":"Sakaguchi","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0115","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb0120","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.4049\/jimmunol.177.10.7398","article-title":"CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients","volume":"177","author":"Miller","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-065X.2001.1820105.x","article-title":"Type 1 T regulatory cells","volume":"182","author":"Roncarolo","year":"2001","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lfs.2021.119132_bb0130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-07-2056","article-title":"Enhanced functionality of CD4+ CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer","volume":"14","author":"Yokokawa","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0135","doi-asserted-by":"crossref","first-page":"G52","DOI":"10.1016\/j.vaccine.2009.09.106","article-title":"Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages","volume":"27","author":"Gray","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2021.119132_bb0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1097-0045(19970401)31:1<61::AID-PROS10>3.0.CO;2-M","article-title":"TGF\u03b2 in prostate cancer: a growth inhibitor that can enhance tumorigenicity","volume":"31","author":"Barrack","year":"1997","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb0145","first-page":"711","article-title":"Role of interleukin 10 and transforming growth factor \u03b21 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice","volume":"5","author":"Stearns","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0150","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2010.34.5025","article-title":"Immunotherapy for prostate cancer: biology and therapeutic approaches","volume":"29","author":"Cha","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb0155","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-03-0165","article-title":"Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers","volume":"10","author":"Koopmann","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0160","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00002371-200205000-00002","article-title":"Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?","volume":"25","author":"Antony","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.lfs.2021.119132_bb0165","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0897.2005.00330.x","article-title":"Regulatory T cells in ovarian cancer: biology and therapeutic potential","volume":"54","author":"Barnett","year":"2005","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0170","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0175","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s13277-013-0832-x","article-title":"Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumor Biol."},{"key":"10.1016\/j.lfs.2021.119132_bb0180","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1038\/emm.2017.313","article-title":"Transcriptional regulation and development of regulatory T cells","volume":"50","author":"Lee","year":"2018","journal-title":"Experimental molecular medicine"},{"key":"10.1016\/j.lfs.2021.119132_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003319","article-title":"Regulatory T cells negatively affect IL-2 production of effector T cells through CD39\/adenosine pathway in HIV infection","volume":"9","author":"Jenabian","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2021.119132_bb0190","doi-asserted-by":"crossref","unstructured":"D. Mougiakakos, A. Choudhury, A. Lladser, R. Kiessling, C.C. Johansson, Regulatory T cells in cancer, in: Advances in cancer research, Elsevier, 2010, pp. 57\u2013117.","DOI":"10.1016\/S0065-230X(10)07003-X"},{"key":"10.1016\/j.lfs.2021.119132_bb0195","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/blood-2011-11-392324","article-title":"Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells","volume":"119","author":"Duhen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2021.119132_bb0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2021.119132_bb0205","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119132_bb0210","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119132_bb0215","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clim.2013.01.004","article-title":"Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity","volume":"146","author":"Goudy","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0220","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4049\/jimmunol.108.3.586","article-title":"Suppressor T cells","volume":"108","author":"Gershon","year":"1972","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.lfs.2021.119132_bb0225","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0230","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0235","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni0901-816","article-title":"Regulatory T cells in the control of immune pathology","volume":"2","author":"Maloy","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0240","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1084\/jem.20070081","article-title":"Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease","volume":"204","author":"Sather","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0245","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1172\/JCI78089","article-title":"T cells in the control of organ-specific autoimmunity","volume":"125","author":"Bluestone","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2021.119132_bb0255","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/pros.23808","article-title":"PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells","volume":"79","author":"Vidotto","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb0260","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0265","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2, 3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0270","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/eji.200425143","article-title":"Distinct roles of CTLA-4 and TGF-\u03b2 in CD4+ CD25+ regulatory T cell function","volume":"34","author":"Tang","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0275","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1073\/pnas.0701171104","article-title":"Adaptive TGF-\u03b2-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment","volume":"104","author":"You","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb0285","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2021.119132_bb0290","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.4049\/jimmunol.0802535","article-title":"A central role for induced regulatory T cells in tolerance induction in experimental colitis","volume":"182","author":"Haribhai","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0295","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/86302","article-title":"Thymic selection of CD4+ CD25+ regulatory T cells induced by an agonist self-peptide","volume":"2","author":"Jordan","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0300","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","article-title":"B7\/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes","volume":"12","author":"Salomon","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2021.119132_bb0305","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni1160","article-title":"CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2","volume":"6","author":"Tai","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0310","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+ CD25\u2212 naive T cells to CD4+ CD25+ regulatory T cells by TGF-\u03b2 induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nri.2016.26","article-title":"T cell receptor signalling in the control of regulatory T cell differentiation and function","volume":"16","author":"Li","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0325","first-page":"771","article-title":"Foxp3-dependent programme of regulatory T-cell differentiation","volume":"445","author":"Gavin","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2021.119132_bb0330","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.immuni.2007.11.022","article-title":"Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire","volume":"28","author":"Burchill","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2021.119132_bb0335","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4049\/jimmunol.178.1.280","article-title":"IL-2 receptor \u03b2-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells","volume":"178","author":"Burchill","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0340","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.immuni.2007.11.021","article-title":"A two-step process for thymic regulatory T cell development","volume":"28","author":"Lio","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2021.119132_bb0345","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/eji.200839196","article-title":"Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions","volume":"39","author":"Duarte","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0350","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1073\/pnas.0811556106","article-title":"Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity","volume":"106","author":"Komatsu","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb0355","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ni.1774","article-title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo","volume":"10","author":"Zhou","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0360","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00008480-200112000-00007","article-title":"IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena","volume":"13","author":"Bennett","year":"2001","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.lfs.2021.119132_bb0365","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ni1455","article-title":"Foxp3 in control of the regulatory T cell lineage","volume":"8","author":"Zheng","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0370","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0167-5699(96)80606-2","article-title":"The expanding universe of T-cell subsets: Th1, Th2 and more","volume":"17","author":"Mosmann","year":"1996","journal-title":"Immunol. Today"},{"key":"10.1016\/j.lfs.2021.119132_bb0375","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1084\/jem.171.4.979","article-title":"Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function","volume":"171","author":"Daynes","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0380","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.4049\/jimmunol.160.12.5719","article-title":"Factors involved in the differentiation of TGF-\u03b2-producing cells from naive CD4+ T cells: IL-4 and IFN-\u03b3 have opposing effects, while TGF-\u03b2 positively regulates its own production","volume":"160","author":"Seder","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.jid.5700004","article-title":"Regulatory T cells","volume":"126","author":"Beissert","year":"2006","journal-title":"The Journal of investigative dermatology"},{"key":"10.1016\/j.lfs.2021.119132_bb0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1471-4906(02)02288-3","article-title":"Pathogen-specific regulatory T cells provoke a shift in the Th1\/Th2 paradigm in immunity to infectious diseases","volume":"23","author":"McGuirk","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0400","doi-asserted-by":"crossref","unstructured":"M. Matsuda, T. Terada, K. Kitatani, R. Kawata, T. Nabe, [Analyses of Foxp3(+) Treg cells and Tr1 cells in subcutaneous immunotherapy-treated allergic individuals in humans and mice], Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 154 (2019) 17\u201322.","DOI":"10.1254\/fpj.154.17"},{"key":"10.1016\/j.lfs.2021.119132_bb0405","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nri1485","article-title":"Regulatory T cells: friend or foe in immunity to infection?","volume":"4","author":"Mills","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0410","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1182\/blood-2003-04-1320","article-title":"Human CD8+ CD25+ thymocytes share phenotypic and functional features with CD4+ CD25+ regulatory thymocytes","volume":"102","author":"Cosmi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2021.119132_bb0415","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0198-8859(02)00742-5","article-title":"Regulatory CD8+ CD28\u2212 T cells in heart transplant recipients","volume":"64","author":"Colovai","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0420","doi-asserted-by":"crossref","unstructured":"E. Uss, A.T. Rowshani, B. Hooibrink, N.M. Lardy, R.A. van Lier, I.J.J.T.J.o.I. ten Berge, CD103 is a marker for alloantigen-induced regulatory CD8+ T cells, 177 (2006) 2775\u20132783.","DOI":"10.4049\/jimmunol.177.5.2775"},{"key":"10.1016\/j.lfs.2021.119132_bb0425","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-8722-1-16","article-title":"Novel therapies in breast cancer: what is new from ASCO 2008","volume":"1","author":"Chu","year":"2008","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb0430","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.20011347","article-title":"Regulatory CD4+ CD25+ T cells restrict memory CD8+ T cell responses","volume":"196","author":"Kursar","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0435","first-page":"48","article-title":"Tumor-derived CD4+ CD25+ regulatory T cell suppression of dendritic cell function involves TGF-\u03b2 and IL-10, Cancer Immunology","volume":"56","author":"Larmonier","year":"2007","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2021.119132_bb0440","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.4049\/jimmunol.172.8.4676","article-title":"Cutting edge: human CD4+ CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells","volume":"172","author":"Misra","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0445","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.humimm.2004.12.006","article-title":"Modulation of monocyte\/macrophage function by human CD4+ CD25+ regulatory T cells","volume":"66","author":"Taams","year":"2005","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0450","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"Collison L and Workman CJ: How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.lfs.2021.119132_bb0455","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2217\/fon.14.298","article-title":"The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia","volume":"11","author":"Yousefi","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb0460","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4049\/jimmunol.179.1.365","article-title":"IL-10 controls ultraviolet-induced carcinogenesis in mice","volume":"179","author":"Loser","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0465","doi-asserted-by":"crossref","first-page":"8479","DOI":"10.1158\/0008-5472.CAN-05-1319","article-title":"Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses","volume":"65","author":"Dercamp","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0470","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri704","article-title":"Transforming growth factor-\u03b2 in T-cell biology","volume":"2","author":"Gorelik","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0475","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-\u03b2 regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0480","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2021.119132_bb0485","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0490","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.4049\/jimmunol.0803646","article-title":"Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner","volume":"182","author":"Collison","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0495","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.autrev.2008.03.001","article-title":"Mechanisms of T regulatory cell function","volume":"7","author":"Askenasy","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.lfs.2021.119132_bb0500","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/blood-2006-04-016451","article-title":"Galectin-1: a key effector of regulation mediated by CD4+ CD25+ T cells","volume":"109","author":"Gar\u00edn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2021.119132_bb0505","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.4049\/jimmunol.174.4.1783","article-title":"Cutting edge: contact-mediated suppression by CD4+ CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism","volume":"174","author":"Gondek","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0510","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.4049\/jimmunol.174.4.2228","article-title":"Induction of cell cycle arrest in lymphocytes by Actinobacillus actinomycetemcomitans cytolethal distending toxin requires three subunits for maximum activity","volume":"174","author":"Shenker","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0515","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4049\/jimmunol.182.3.1469","article-title":"Human circulating CD4+ CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis","volume":"182","author":"Strauss","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0520","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1681\/ASN.2012010070","article-title":"Autocrine adenosine signaling promotes regulatory T cell\u2013mediated renal protection","volume":"23","author":"Kinsey","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119132_bb0525","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fimmu.2012.00190","article-title":"The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway","volume":"3","author":"Ohta","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0530","doi-asserted-by":"crossref","first-page":"106087","DOI":"10.1016\/j.intimp.2019.106087","article-title":"Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target","volume":"78","author":"Hashemi","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2021.119132_bb0535","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.180.6.2049","article-title":"Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1","volume":"180","author":"Peach","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0540","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","article-title":"CTLA-4 ligation blocks CD28-dependent T cell activation","volume":"183","author":"Walunas","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0545","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0550","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1582-4934.2011.01437.x","article-title":"Regulatory T cell: a protection for tumour cells","volume":"16","author":"Wang","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0555","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1084\/jem.20122759","article-title":"IL-2 coordinates IL-2\u2013producing and regulatory T cell interplay","volume":"210","author":"Amado","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0560","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ni.2649","article-title":"Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells","volume":"14","author":"Pierson","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0565","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.immuni.2013.02.022","article-title":"Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals","volume":"38","author":"Tai","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2021.119132_bb0570","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0575","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2021.119132_bb0580","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2021.119132_bb0585","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2021.119132_bb0590","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/CJI.0b013e3181f4c208","article-title":"A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients","volume":"33","author":"Adotevi","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.lfs.2021.119132_bb0595","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijc.25674","article-title":"Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients","volume":"129","author":"Desar","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0600","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1090075","article-title":"Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model","volume":"5","author":"Chang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lfs.2021.119132_bb0605","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119132_bb0610","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0615","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119132_bb0620","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia\u2013lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb0625","doi-asserted-by":"crossref","unstructured":"M. Ogura, T. Ishida, K. Hatake, M. Taniwaki, K. Ando, K. Tobinai, K. Fujimoto, K. Yamamoto, T. Miyamoto, N. Uike, Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma, Journal of Clinical Oncology, 32 (2014) 1157\u20131163.","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"10.1016\/j.lfs.2021.119132_bb0630","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(02)03143-5","article-title":"Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4","volume":"527","author":"Hatse","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2021.119132_bb0635","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2021.119132_bb0640","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-15-1412","article-title":"Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity","volume":"22","author":"Kreitman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0645","doi-asserted-by":"crossref","unstructured":"A.J. Rech, R. Mick, S. Martin, A. Recio, N.A. Aqui, D.J. Powell, T.A. Colligon, J.A. Trosko, L.I. Leinbach, C.H. Pletcher, CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients, Science translational medicine, 4 (2012) 134ra162-134ra162.","DOI":"10.1126\/scitranslmed.3003330"},{"key":"10.1016\/j.lfs.2021.119132_bb0650","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","article-title":"Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells","volume":"115","author":"Dannull","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2021.119132_bb0655","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.cji.0000175468.19742.10","article-title":"Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma","volume":"28","author":"Attia","year":"2005","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"key":"10.1016\/j.lfs.2021.119132_bb0660","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2014.237","article-title":"Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I\/II study","volume":"28","author":"Maury","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2021.119132_bb0665","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti\u2013cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb0670","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0675","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti\u2013CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0680","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0685","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma","volume":"17","author":"Hodi","year":"2016","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.lfs.2021.119132_bb0690","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.lfs.2021.119132_bb0695","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3389\/fimmu.2017.01578","article-title":"Tregs: where we are and what comes next?","volume":"8","author":"Zhao","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0700","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0705","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00262-010-0866-5","article-title":"Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy","volume":"59","author":"Coe","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2021.119132_bb0710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010436","article-title":"Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation","volume":"5","author":"Cohen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119132_bb0715","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.coi.2011.12.011","article-title":"Modulation of GITR for cancer immunotherapy","volume":"24","author":"Schaer","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0720","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-12-36","article-title":"Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs","volume":"12","author":"Lu","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0725","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20050940","article-title":"Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells","volume":"202","author":"Ko","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0730","first-page":"2172","article-title":"Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice","volume":"123","author":"Murphy","year":"2014","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.lfs.2021.119132_bb0735","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.06.028","article-title":"Rationale for anti-GITR cancer immunotherapy","volume":"67","author":"Knee","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0745","doi-asserted-by":"crossref","unstructured":"A.M. Lesokhin, M.K. Callahan, M.A. Postow, J.D. Wolchok, On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation, Science translational medicine, 7 (2015) 280sr281-280sr281.","DOI":"10.1126\/scitranslmed.3010274"},{"key":"10.1016\/j.lfs.2021.119132_bb0750","series-title":"TNFR agonists: a review of current biologics targeting OX40, 4-1BB, CD27, and GITR, American Journal of Hematology\/Oncology\u00ae, 13","author":"Sturgill","year":"2017"},{"key":"10.1016\/j.lfs.2021.119132_bb0755","series-title":"Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs, Science Signaling, 10","author":"Torrey","year":"2017"},{"key":"10.1016\/j.lfs.2021.119132_bb0760","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2021.119132_bb0765","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor \u03b6-chain and induce a regulatory phenotype in naive T cells","volume":"176","author":"Fallarino","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0770","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0775","first-page":"6102","article-title":"Indoleamine 2, 3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes","volume":"113","author":"Sharma","year":"2009","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.lfs.2021.119132_bb0780","doi-asserted-by":"crossref","first-page":"43005","DOI":"10.18632\/oncotarget.5656","article-title":"TGF-\u03b2 blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner","volume":"6","author":"Soares","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119132_bb0785","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1084\/jem.20041684","article-title":"Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors","volume":"201","author":"Yu","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0790","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0795","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0800","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.2147\/CMAR.S228887","article-title":"T-regulatory cells in tumor progression and therapy","volume":"11","author":"Verma","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0805","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/08923973.2011.619987","article-title":"The deviated balance between regulatory T cell and Th17 in autoimmunity","volume":"34","author":"Jadidi-Niaragh","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.lfs.2021.119132_bb0810","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0815","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"3","author":"Vacchelli","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lfs.2021.119132_bb0820","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2005-07-2737","article-title":"Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines","volume":"107","author":"Zhou","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2021.119132_bb0825","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI31202","article-title":"Tregs and rethinking cancer immunotherapy","volume":"117","author":"Curiel","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2021.119132_bb0830","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.lfs.2021.119132_bb0835","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1158\/1078-0432.CCR-04-2237","article-title":"The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors","volume":"11","author":"Kudo-Saito","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0840","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.4049\/jimmunol.176.5.2722","article-title":"Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines","volume":"176","author":"Taieb","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb0845","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","article-title":"Prostate cancer epidemiology","volume":"361","author":"Gr\u00f6nberg","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.119132_bb0850","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2021.119132_bb0855","doi-asserted-by":"crossref","unstructured":"D.G. Bostwick, H.B. Burke, D. Djakiew, S. Euling, S.m. Ho, J. Landolph, H. Morrison, B. Sonawane, T. Shifflett, D.J. Waters, Human prostate cancer risk factors, Cancer: Interdisciplinary International Journal of the American Cancer Society, 101 (2004) 2371\u20132490.","DOI":"10.1002\/cncr.20408"},{"key":"10.1016\/j.lfs.2021.119132_bb0860","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1464-410X.2004.04795.x","article-title":"Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies","volume":"93","author":"Dagnelie","year":"2004","journal-title":"BJU Int."},{"key":"10.1016\/j.lfs.2021.119132_bb0865","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-118-10-199305150-00007","article-title":"Risk factors for prostate cancer","volume":"118","author":"Pienta","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lfs.2021.119132_bb0870","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/oxfordjournals.epirev.a000798","article-title":"Fat, meat, and prostate cancer","volume":"23","author":"Kolonel","year":"2001","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.lfs.2021.119132_bb0875","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrc1389","article-title":"The multiethnic cohort study: exploring genes, lifestyle and cancer risk","volume":"4","author":"Kolonel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0880","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2016.09.026","article-title":"Diet, body size, physical activity and risk of prostate cancer: an umbrella review of the evidence","volume":"69","author":"Markozannes","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0885","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/aja.2011.142","article-title":"Lifestyle and dietary factors in the prevention of lethal prostate cancer","volume":"14","author":"Wilson","year":"2012","journal-title":"Asian journal of andrology"},{"key":"10.1016\/j.lfs.2021.119132_bb0890","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/02841860510029572","article-title":"Diet, lifestyle and risk of prostate cancer","volume":"44","author":"Wolk","year":"2005","journal-title":"Acta Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb0895","first-page":"28","article-title":"Epidemiology","volume":"8","author":"Barsouk","year":"2020","journal-title":"Staging and Management of Prostate Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0900","first-page":"807","article-title":"Prostate cancer: 3. Individual risk factors","volume":"159","author":"Gallagher","year":"1998","journal-title":"Cmaj"},{"key":"10.1016\/j.lfs.2021.119132_bb0905","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0022-5347(05)64541-7","article-title":"Hereditary prostate cancer: clinical aspects","volume":"168","author":"Bratt","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.lfs.2021.119132_bb0910","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1136\/jmg.40.3.e21","article-title":"RNASEL mutations in hereditary prostate cancer","volume":"40","author":"Chen","year":"2003","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.lfs.2021.119132_bb0915","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nature06042","article-title":"Small self-RNA generated by RNase L amplifies antiviral innate immunity","volume":"448","author":"Malathi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119132_bb0920","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1093\/emboj\/16.21.6355","article-title":"Interferon action and apoptosis are defective in mice devoid of 2\u2032, 5\u2032-oligoadenylate-dependent RNase L","volume":"16","author":"Zhou","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.lfs.2021.119132_bb0925","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1086\/344516","article-title":"Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer","volume":"71","author":"Camp","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.lfs.2021.119132_bb0930","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1038\/sj.onc.1209571","article-title":"ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-\u03b2\/Smad-induced growth arrest of prostate cells","volume":"25","author":"Noda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2021.119132_bb0935","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng994","article-title":"Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk","volume":"32","author":"Xu","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2021.119132_bb0940","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/humu.20271","article-title":"Germline mutations of the MSR1 gene in prostate cancer families from Germany","volume":"27","author":"Maier","year":"2006","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.lfs.2021.119132_bb0945","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/ng1239","article-title":"No association of germline alteration of MSR1 with prostate cancer risk","volume":"35","author":"Wang","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2021.119132_bb0950","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature05609","article-title":"A recurrent mutation in PALB2 in Finnish cancer families","volume":"446","author":"Erkko","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119132_bb0955","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb0960","doi-asserted-by":"crossref","unstructured":"N. Mottet, J. Bellmunt, M. Bolla, E. Briers, M.G. Cumberbatch, M. De Santis, N. Fossati, T. Gross, A.M. Henry, S. Joniau, EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, European urology, 71 (2017) 618\u2013629.","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"10.1016\/j.lfs.2021.119132_bb0965","doi-asserted-by":"crossref","unstructured":"V.J.J.E.R.o.M.D. Gnanapragasam, Molecular markers to guide primary radical treatment selection in localized prostate cancer, 14 (2014) 871\u2013881.","DOI":"10.1586\/14737159.2014.936851"},{"key":"10.1016\/j.lfs.2021.119132_bb0970","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"Jama"},{"key":"10.1016\/j.lfs.2021.119132_bb0975","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajur.2018.11.007","article-title":"Diagnosis of prostate cancer","volume":"6","author":"Descotes","year":"2019","journal-title":"Asian journal of urology"},{"key":"10.1016\/j.lfs.2021.119132_bb0980","doi-asserted-by":"crossref","unstructured":"S.A. Rosenthal, D. Hunt, A.O. Sartor, K.J. Pienta, L. Gomella, D. Grignon, R. Rajan, K.J. Kerlin, C.U. Jones, M. Dobelbower, A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902, International Journal of Radiation Oncology* Biology* Physics, 93 (2015) 294\u2013302.","DOI":"10.1016\/j.ijrobp.2015.05.024"},{"key":"10.1016\/j.lfs.2021.119132_bb0985","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.eururo.2007.10.008","article-title":"Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy","volume":"53","author":"Yossepowitch","year":"2008","journal-title":"Eur. Urol."},{"key":"10.1016\/j.lfs.2021.119132_bb0990","doi-asserted-by":"crossref","first-page":"T209","DOI":"10.1530\/ERC-15-0217","article-title":"Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications","volume":"22","author":"Deng","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb0995","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/2159-8290.CD-13-0679","article-title":"Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer","volume":"3","author":"Bartek","year":"2013","journal-title":"Cancer discovery"},{"key":"10.1016\/j.lfs.2021.119132_bb1000","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1158\/1078-0432.CCR-04-2140","article-title":"Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer","volume":"11","author":"Eigl","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.21037\/tau.2018.03.07","article-title":"Chemotherapy and radiation for prostate cancer","volume":"7","author":"Hurwitz","year":"2018","journal-title":"Translational andrology and urology"},{"key":"10.1016\/j.lfs.2021.119132_bb1010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.canlet.2015.12.022","article-title":"Regulation of prostate cancer progression by the tumor microenvironment","volume":"380","author":"Shiao","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2021.119132_bb1015","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/ijms20051057","article-title":"A novel specific anti-CD73 antibody inhibits triple-negative breast cancer cell motility by regulating autophagy","volume":"20","author":"Qiao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb1020","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0022-5347(05)65620-0","article-title":"Reactive stroma in prostate cancer progression","volume":"166","author":"Tuxhorn","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.lfs.2021.119132_bb1025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: biology and emerging therapeutic opportunities","volume":"12","author":"Andaloussi","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2021.119132_bb1030","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/onc.2013.191","article-title":"Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression","volume":"33","author":"Comito","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2021.119132_bb1035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/0008-5472.CAN-14-0992","article-title":"CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy","volume":"75","author":"Escamilla","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1040","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb1045","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1172\/JCI69369","article-title":"Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis","volume":"123","author":"Liu","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2021.119132_bb1050","doi-asserted-by":"crossref","first-page":"14360","DOI":"10.18632\/oncotarget.3965","article-title":"Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer","volume":"6","author":"Pasero","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119132_bb1055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2353\/ajpath.2010.100070","article-title":"Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy","volume":"177","author":"Johansson","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2021.119132_bb1060","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/cncr.28890","article-title":"Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio","volume":"120","author":"Templeton","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb1065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","article-title":"Multiple roles for CD4+ T cells in anti-tumor immune responses","volume":"222","author":"Kennedy","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lfs.2021.119132_bb1070","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ccr.2014.04.026","article-title":"B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas","volume":"25","author":"Affara","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2021.119132_bb1075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature14395","article-title":"Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy","volume":"521","author":"Shalapour","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119132_bb1080","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb1085","first-page":"891","article-title":"Phase I\/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer, Cancer Immunology","volume":"66","author":"Lilleby","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2021.119132_bb1090","series-title":"A Clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer, in","author":"Shore","year":"2017"},{"key":"10.1016\/j.lfs.2021.119132_bb1095","first-page":"1345","article-title":"Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer, Cancer Immunology","volume":"66","author":"Sonpavde","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2021.119132_bb1100","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317695021","article-title":"Increased efficacy of a dendritic cell\u2013based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor","volume":"39","author":"Arab","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.lfs.2021.119132_bb1105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nrurol.2017.77","article-title":"Personalized peptide vaccines and their relation to other therapies in urological cancer","volume":"14","author":"Kimura","year":"2017","journal-title":"Nature Reviews Urology"},{"key":"10.1016\/j.lfs.2021.119132_bb1110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","article-title":"A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer","volume":"70","author":"Yoshimura","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.lfs.2021.119132_bb1115","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb1120","doi-asserted-by":"crossref","unstructured":"M. Haji-Fatahaliha, M. Hosseini, A. Akbarian, S. Sadreddini, F. Jadidi-Niaragh, M. Yousefi, CAR-modified T-cell therapy for cancer: an updated review, Artificial cells, nanomedicine, and biotechnology, 44 (2016) 1339\u20131349.","DOI":"10.3109\/21691401.2015.1052465"},{"key":"10.1016\/j.lfs.2021.119132_bb1125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2021.119132_bb1130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-017-0232-7","article-title":"Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients","volume":"5","author":"Cabel","year":"2017","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb1135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in Enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119132_bb1140","series-title":"PD-L1 blockade in preclinical models of PTEN-deficient prostate cancer, in","author":"De Velasco","year":"2017"},{"key":"10.1016\/j.lfs.2021.119132_bb1145","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1150","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119132_bb1155","series-title":"First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC), Annals of oncology, 27","author":"Graff","year":"2016"},{"key":"10.1016\/j.lfs.2021.119132_bb1160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOU.0000000000000462","article-title":"Prostate cancer immunotherapy: where are we and where are we going?","volume":"28","author":"De Velasco","year":"2018","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.lfs.2021.119132_bb1165","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.lfs.2021.119132_bb1170","doi-asserted-by":"crossref","unstructured":"Y. Pu, M. Xu, Y. Liang, K. Yang, Y. Guo, X. Yang, Y.-X. Fu, Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse, Science translational medicine, 8 (2016) 333ra347-333ra347.","DOI":"10.1126\/scitranslmed.aad5659"},{"key":"10.1016\/j.lfs.2021.119132_bb1175","series-title":"A phase II study combining ipilimumab and degarelix with or without radical prostatectomy (RP) in men with newly diagnosed metastatic noncastration prostate cancer (mNCPC) or biochemically recurrent (BR) NCPC, in","author":"Autio","year":"2017"},{"key":"10.1016\/j.lfs.2021.119132_bb1180","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1078-0432.CCR-16-1780","article-title":"Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: a phase II randomized trial","volume":"23","author":"Antonarakis","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1185","series-title":"Long-Term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate+ prednisone in metastatic castration-resistant prostate cancer patients (pts), in","author":"Small","year":"2017"},{"key":"10.1016\/j.lfs.2021.119132_bb1190","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/modpathol.2012.164","article-title":"CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer","volume":"26","author":"Davidsson","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lfs.2021.119132_bb1195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/pros.23442","article-title":"FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer","volume":"78","author":"Davidsson","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb1200","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","article-title":"CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer","volume":"13","author":"Kiniwa","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1205","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.4049\/jimmunol.1201744","article-title":"Human prostate tumor antigen\u2013specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade","volume":"189","author":"Olson","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb1210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cyto.2018.07.006","article-title":"Serum concentration of interleukin-35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer","volume":"113","author":"Chatrabnous","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.lfs.2021.119132_bb1215","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ccr.2009.08.016","article-title":"Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate","volume":"16","author":"Wang","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2021.119132_bb1220","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.28026","article-title":"Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer","volume":"133","author":"Huen","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb1225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/pros.23742","article-title":"M2 macrophages and regulatory T cells in lethal prostate cancer","volume":"79","author":"Erlandsson","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb1230","doi-asserted-by":"crossref","unstructured":"M. Idorn, T. K\u00f8llgaard, P. Kongsted, L. Sengel\u00f8v, P. thor Straten, Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer, Cancer immunology, immunotherapy, 63 (2014) 1177\u20131187.","DOI":"10.1007\/s00262-014-1591-2"},{"key":"10.1016\/j.lfs.2021.119132_bb1235","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/pros.20538","article-title":"The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2\u03b1 but not HIF-1\u03b1","volume":"67","author":"Fox","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb1240","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/0008-5472.CAN-07-2429","article-title":"Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+ CD25+ regulatory T cells","volume":"68","author":"Degl\u2019Innocenti","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1245","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/pros.22858","article-title":"Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer","volume":"74","author":"Klyushnenkova","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb1250","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1073\/pnas.1203479109","article-title":"Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model","volume":"109","author":"Yu","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb1255","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/pros.23890","article-title":"Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis","volume":"79","author":"Watanabe","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2021.119132_bb1260","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-10-2804","article-title":"Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients","volume":"17","author":"Sorrentino","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1265","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1158\/0008-5472.CAN-09-2490","article-title":"In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice","volume":"70","author":"Akins","year":"2010","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.lfs.2021.119132_bb1270","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","article-title":"T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer","volume":"26","author":"Obradovic","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119132_bb1275","unstructured":"L. Shen, M. Ciesielski, S. Ramakrishnan, K.M. Miles, L. Ellis, Class I histone deacetylase inhibitor entinostat suppresses regulatory t cells and, (2012)."},{"key":"10.1016\/j.lfs.2021.119132_bb1280","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/cas.13639","article-title":"Norcantharidin enhances antitumor immunity of GM-CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells","volume":"109","author":"Mo","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lfs.2021.119132_bb1285","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ijc.32803","article-title":"Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer","volume":"147","author":"Laheurte","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb1290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-010-0927-9","article-title":"Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre-versus post-vaccination","volume":"60","author":"Vergati","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2021.119132_bb1295","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1016\/j.vaccine.2017.08.093","article-title":"Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer","volume":"35","author":"Mo","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2021.119132_bb1300","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/aja.2013.22","article-title":"Analysis of circulating regulatory T cells (CD4+ CD25+ CD127\u2212) after cryosurgery in prostate cancer","volume":"15","author":"Si","year":"2013","journal-title":"Asian journal of andrology"},{"key":"10.1016\/j.lfs.2021.119132_bb1305","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119132_bb1310","doi-asserted-by":"crossref","unstructured":"A. Heidenreich, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, N. Mottet, H.-P. Schmid, T. van der Kwast, T. Wiegel, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, European urology, 59 (2011) 61\u201371.","DOI":"10.1016\/j.eururo.2010.10.039"},{"key":"10.1016\/j.lfs.2021.119132_bb1315","article-title":"Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?","volume":"11","author":"Cho","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119132_bb1320","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature17954","article-title":"Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy","volume":"533","author":"Li","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119132_bb1325","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ni1179","article-title":"A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2021.119132_bb1330","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2021.119132_bb1335","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat. Rev. Immunol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052100117X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052100117X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:27:54Z","timestamp":1752568074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052100117X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":262,"alternative-id":["S002432052100117X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119132","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of regulatory T cells in the pathogenesis and treatment of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"119132"}}